Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register Genesis for InfoPages here.
Genesis - Latest News [Page 3]
Genesis Research Announces Full Year Result
Friday, 13 February 2004, 6:25 pm | Genesis
Genesis Research and Development Corporation Ltd (NZX/ASX: GEN) ended the twelve-month period to 31 December 2003 with a cash balance of $23.0 million (2002: $36.3 million). This position is in line with budget and will be supported by ongoing revenue streams ... More >>
Students Sacrifice Summer Sun for Science Forum
Sunday, 11 January 2004, 3:49 pm | Genesis
A record 144 of New Zealand’s sharpest young scientific minds are gathering in Auckland this weekend for the fifteenth annual Genesis Research and Development Science and Technology Forum. More >>
Genesis Research Provide Update On PVAC™ Treatment
Tuesday, 23 December 2003, 5:29 pm | Genesis
Auckland and Seattle, December 22, 2003 – Genesis Research and Development Corporation Ltd (NZX/ASX: GEN) and Corixa Corporation (Nasdaq: CRXA) today announced that the companies have discontinued the development of PVAC™, a product candidate for the ... More >>
Plant Science Business To AgriGenesis Biosciences
Wednesday, 17 December 2003, 11:07 am | Genesis
Genesis Research and Development Corporation (NZX/ASX: GEN) confirms that it has completed the transfer of its plant sciences business to a wholly owned subsidiary, AgriGenesis Biosciences Limited, which is now trading as an independently managed ... More >>
Phase II Trial of AVAC™ in Childhood Eczema
Wednesday, 10 September 2003, 12:24 am | Genesis
Genesis Research and Development Corporation (NZX/ASX: GEN) and its partner, London-based biopharmaceutical company SR Pharma (LSE: SPA) today announced the commencement of a randomised, placebo-controlled Phase II trial of AVAC™ in paediatric atopic dermatitis ... More >>
Genesis Research Announces Half Year Result
Wednesday, 6 August 2003, 11:47 am | Genesis
Genesis Research and Development Corporation Ltd (NZX/ASX: GEN) today announced its financial results for the six-month period to June 30. More >>
Genesis Research Appoints Chief Executive
Tuesday, 5 August 2003, 4:46 pm | Genesis
Genesis Research and Development Corporation Limited (NZX/ASX: GEN) today announced the appointment of Dr Peter Lee, an expatriate New Zealander, as Chief Executive of AgriGenesis Biosciences limited, its plant science subsidiary that was announced ... More >>
Genesis Research and EvoGenix To Collaborate
Monday, 14 April 2003, 2:48 pm | Genesis
Genesis Research and Development Corporation Limited (NZSE/ASX: GEN) and EvoGenix Pty Limited today announced the signing of a collaboration agreement to undertake a joint research and development program to discover novel anti-inflammatory drugs. More >>
Genesis Awarded $800,000 Grant
Wednesday, 5 March 2003, 3:15 pm | Genesis
Technology New Zealand has awarded Genesis Research and Development Corporation Limited (NZSE /ASX: GEN) a technology development grant of almost $800,000 over two years to support the development of new gene discovery software and capitalise on ... More >>
Phase I Safety Study in Atopic Dermatitis
Wednesday, 5 March 2003, 3:13 pm | Genesis
Genesis Research and Development Corporation (NZSE / ASX: GEN) and SR Pharma plc (LSE: SPA) today announced the successful completion of a Phase I safety study of AVAC™ for the treatment of atopic dermatitis (also known as eczema) in children, ... More >>
Genesis Research Maintains Cash Reserves of $36.3m
Friday, 7 February 2003, 12:43 am | Genesis
Genesis Research and Development Corporation Limited [NZSE & ASX: GEN] today announced that it finished the 2002 year with cash reserves of $36.3 million, sufficient to fund its current and planned research and trial programmes for the foreseeable future. More >>
Keen Young Kiwi Scientists Head Up To The Forum
Friday, 10 January 2003, 11:42 am | Genesis
The keenest science students from around New Zealand are gathering in Auckland this weekend for the 14th annual Genesis Research National Science and Technology Forum. More >>
Phase II trial of SRP299 in childhood eczema
Tuesday, 26 November 2002, 10:09 am | Genesis
Genesis Research and Development Corporation (NZSE/ASX: GEN) and London-based biopharmaceutical company SR Pharma (LSE: SPA), today announced the start of a phase II, randomised, placebo-controlled, trial of SRP299 (a killed Mycobacterium vaccae suspension) for ... More >>
Genesis Establishes High Level Development Team
Thursday, 26 September 2002, 1:19 pm | Genesis
Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that it has enhanced its commercial capability by establishing a strategic development unit. The unit will be charged with identifying programmes, processes and technologies ... More >>
Five Days Left For Next Generation Scientists
Monday, 5 August 2002, 1:57 pm | Genesis
Auckland, 5 August 2002 – Kiwi Year 12 students with a thirst for scientific knowledge have only until Friday to register for New Zealand’s premier international student science programme. Students wanting to apply for the Genesis Research National Science ... More >>
Genesis Research Announces Half Year Result
Monday, 29 July 2002, 10:05 am | Genesis
Genesis Research and Development Corporation Ltd (NZSE / ASX: GEN) today announced results for the six month period to June 30. More >>
Clinical Trial of PVAC™ with UVB in New Zealand
Friday, 28 June 2002, 2:47 pm | Genesis
Randomised, Blinded and Controlled Trial to Evaluate Improvement of Disease Severity in Patients with Mild to Moderate Psoriasis More >>
Genesis Research Confirms Full Listing on ASX
Friday, 28 June 2002, 2:46 pm | Genesis
Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that it has satisfied all Australian Stock Exchange (ASX) requirements and will transfer from a Foreign Exempt listing on ASX to a Full Listing effective 1st July 2002. Genesis ... More >>
Genesis Announces New U.S. Clinical Trial of PVAC™
Friday, 7 June 2002, 10:52 am | Genesis
Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that Corixa Corporation has initiated an additional U.S. clinical study designed to evaluate the potential effectiveness of PVAC™ treatment for patients with mild ... More >>
Results Of Safety Study In Atopic Dermatitis
Friday, 3 May 2002, 11:50 am | Genesis
Genesis Research and Development Corporation today announced that it had completed a Phase I safety study of AVAC™ for the treatment of atopic dermatitis (also known as eczema) in adults, which showed that AVAC™ was safe and well tolerated. This first ... More >>
